eXoZymes Net Income
| EXOZ Stock | 11.19 0.06 0.53% |
As of the 6th of February, EXoZymes shows the Coefficient Of Variation of (8,438), risk adjusted performance of (0.0004), and Standard Deviation of 5.1. eXoZymes technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
EXoZymes' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing EXoZymes' valuation are provided below:We have found one hundred eighteen available fundamental signals for eXoZymes, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of eXoZymes prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to drop to about 67.7 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -5.3 M | -5 M | |
| Net Loss | -5.3 M | -5 M | |
| Net Loss | (0.83) | (0.79) | |
| Net Income Per E B T | 1.17 | 1.13 |
EXoZymes | Net Income | Build AI portfolio with EXoZymes Stock |
The evolution of Net Income for eXoZymes provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how EXoZymes compares to historical norms and industry peers.
Latest EXoZymes' Net Income Growth Pattern
Below is the plot of the Net Income of eXoZymes over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in eXoZymes financial statement analysis. It represents the amount of money remaining after all of eXoZymes operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is EXoZymes' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in EXoZymes' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (5.86 M) | 10 Years Trend |
|
Net Income |
| Timeline |
EXoZymes Net Income Regression Statistics
| Arithmetic Mean | (2,005,398) | |
| Coefficient Of Variation | (81.34) | |
| Mean Deviation | 1,195,856 | |
| Median | (1,209,106) | |
| Standard Deviation | 1,631,285 | |
| Sample Variance | 2.7T | |
| Range | 4.7M | |
| R-Value | (0.70) | |
| Mean Square Error | 1.5T | |
| R-Squared | 0.48 | |
| Significance | 0 | |
| Slope | (224,728) | |
| Total Sum of Squares | 42.6T |
EXoZymes Net Income History
Other Fundumenentals of eXoZymes
EXoZymes Net Income component correlations
EXoZymes Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for EXoZymes is extremely important. It helps to project a fair market value of EXoZymes Stock properly, considering its historical fundamentals such as Net Income. Since EXoZymes' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of EXoZymes' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of EXoZymes' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of EXoZymes. Projected growth potential of EXoZymes fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive EXoZymes assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate eXoZymes using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating EXoZymes' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause EXoZymes' market price to deviate significantly from intrinsic value.
It's important to distinguish between EXoZymes' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding EXoZymes should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, EXoZymes' market price signifies the transaction level at which participants voluntarily complete trades.
EXoZymes 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to EXoZymes' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of EXoZymes.
| 11/08/2025 |
| 02/06/2026 |
If you would invest 0.00 in EXoZymes on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding eXoZymes or generate 0.0% return on investment in EXoZymes over 90 days. EXoZymes is related to or competes with Estrella Immunopharma, Greenwich Lifesciences, Atossa Genetics, Tiziana Life, Tevogen Bio, Surrozen, and Oncolytics Biotech. EXoZymes is entity of United States. It is traded as Stock on NASDAQ exchange. More
EXoZymes Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure EXoZymes' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess eXoZymes upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.02) | |||
| Maximum Drawdown | 26.73 | |||
| Value At Risk | (6.95) | |||
| Potential Upside | 11.43 |
EXoZymes Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for EXoZymes' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as EXoZymes' standard deviation. In reality, there are many statistical measures that can use EXoZymes historical prices to predict the future EXoZymes' volatility.| Risk Adjusted Performance | (0.0004) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.06) |
EXoZymes February 6, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.0004) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 3.51 | |||
| Coefficient Of Variation | (8,438) | |||
| Standard Deviation | 5.1 | |||
| Variance | 26.01 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 26.73 | |||
| Value At Risk | (6.95) | |||
| Potential Upside | 11.43 | |||
| Skewness | 0.8531 | |||
| Kurtosis | 1.77 |
eXoZymes Backtested Returns
eXoZymes secures Sharpe Ratio (or Efficiency) of -0.11, which denotes the company had a -0.11 % return per unit of risk over the last 3 months. eXoZymes exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm EXoZymes' Risk Adjusted Performance of (0.0004), coefficient of variation of (8,438), and Standard Deviation of 5.1 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 1.27, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, EXoZymes will likely underperform. At this point, eXoZymes has a negative expected return of -0.49%. Please make sure to confirm EXoZymes' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if eXoZymes performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.07 |
Very weak reverse predictability
eXoZymes has very weak reverse predictability. Overlapping area represents the amount of predictability between EXoZymes time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of eXoZymes price movement. The serial correlation of -0.07 indicates that barely 7.0% of current EXoZymes price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.07 | |
| Spearman Rank Test | 0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.56 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
EXoZymes Net Interest Income
Net Interest Income |
|
Based on the recorded statements, eXoZymes reported net income of (5.86 Million). This is 101.72% lower than that of the Biotechnology sector and 108.37% lower than that of the Health Care industry. The net income for all United States stocks is 101.03% higher than that of the company.
EXoZymes Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses EXoZymes' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of EXoZymes could also be used in its relative valuation, which is a method of valuing EXoZymes by comparing valuation metrics of similar companies.EXoZymes is currently under evaluation in net income category among its peers.
EXoZymes ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, EXoZymes' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to EXoZymes' managers, analysts, and investors.Environmental | Governance | Social |
EXoZymes Fundamentals
| Return On Equity | -9.41 | ||||
| Return On Asset | -1.0 | ||||
| Current Valuation | 85.77 M | ||||
| Shares Outstanding | 8.4 M | ||||
| Shares Owned By Insiders | 71.62 % | ||||
| Shares Owned By Institutions | 0.72 % | ||||
| Number Of Shares Shorted | 10 K | ||||
| Price To Book | 17.58 X | ||||
| Gross Profit | (700) | ||||
| EBITDA | (5.59 M) | ||||
| Net Income | (5.86 M) | ||||
| Total Debt | 1.39 M | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (8.51 M) | ||||
| Short Ratio | 2.04 X | ||||
| Earnings Per Share | (0.99) X | ||||
| Number Of Employees | 31 | ||||
| Market Capitalization | 94 M | ||||
| Total Asset | 13.03 M | ||||
| Retained Earnings | (11.95 M) | ||||
| Working Capital | 9.49 M | ||||
| Net Asset | 13.03 M |
About EXoZymes Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze eXoZymes's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EXoZymes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of eXoZymes based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for EXoZymes Stock Analysis
When running EXoZymes' price analysis, check to measure EXoZymes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXoZymes is operating at the current time. Most of EXoZymes' value examination focuses on studying past and present price action to predict the probability of EXoZymes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXoZymes' price. Additionally, you may evaluate how the addition of EXoZymes to your portfolios can decrease your overall portfolio volatility.